×
About 145 results

ALLMedicine™ Coronary Drug-eluting Stent Center

Research & Reviews  51 results

Combined Analysis of Two Parallel Randomized Trials of Sirolimus-Coated and Paclitaxel-...
https://doi.org/10.1161/CIRCINTERVENTIONS.122.012305
Circulation. Cardiovascular Interventions; Scheller B, Mangner N et. al.

Sep 21st, 2022 - Paclitaxel-coated balloons (PCBs) are a preferred treatment option for coronary in-stent restenosis. To date, data from randomized trials of alternative drug coatings are lacking. The aim of the randomized Malaysian and German-Swiss randomized tri...

Clinical Outcome of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent Imp...
https://doi.org/10.1007/s10557-022-07363-7
Cardiovascular Drugs and Therapy; Zhang Y, Wu Z et. al.

Aug 6th, 2022 - In-stent chronic total occlusion (IS-CTO) represents a unique challenge for percutaneous coronary intervention. Whether the optimal treatment for IS-CTO is angioplasty with paclitaxel-coated balloons (PCBs) or repeat stenting with drug-eluting ste...

Differential Proteomic Profiles of Coronary Serum Exosomes in Acute Myocardial Infarcti...
https://doi.org/10.1007/s10557-022-07365-5
Cardiovascular Drugs and Therapy; Wang W, Zhao Y et. al.

Jul 14th, 2022 - Delayed re-endothelialization after coronary drug-eluting stent implantation is associated with an increased incidence of late in-stent thrombosis. Serum exosomes exhibit controversial effects on promoting endothelialization. This study aimed to c...

Coronary Drug-Eluting Stent
http://emedicine.medscape.com/article/1970984-overview

Jun 20th, 2022 - Products Drug-eluting stents (DES) are a standard metallic coronary stent with a polymer coating and an antiproliferative drug, which allows drug elution into the coronary wall for weeks to months after stent implantation. Category Drug-eluting st...

Coronary Drug-Eluting Stent
https://emedicine.medscape.com/article/1970984-print

Jun 20th, 2022 - Drug-eluting stents (DES) are a standard metallic coronary stent with a polymer coating and an antiproliferative drug, which allows drug elution into the coronary wall for weeks to months after stent implantation. Category Drug-eluting stents (DES...

see more →

Clinicaltrials.gov  4 results

Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon
https://clinicaltrials.gov/ct2/show/NCT02996318

Aug 27th, 2021 - The aim of the study is to investigate the non-inferiority of the new sirolimus-coated balloon catheters in comparison to the paclitaxel-coated SQP with regard to acute tolerance, safety and efficacy in coronary DES in-stent restenosis. Patient po...

NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial
https://clinicaltrials.gov/ct2/show/NCT01303640

Dec 10th, 2015 - Everolimus-eluting stent is the most widely used coronary drug-eluting stent in Japan. Biolimus-eluting stent is a new coronary drug-eluting stent, which is going to be approved in 2011 by the Japanese Ministry of Health, Labor and Welfare. It has...

Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting Stent Trial
https://clinicaltrials.gov/ct2/show/NCT01035450

Dec 10th, 2015 - Sirolimus-eluting stent is the most widely used coronary drug-eluting stent in Japan. Everolimus-eluting stent is a new coronary drug-eluting stent, which is going to be approved in the first quarter of 2010 by the Japanese Ministry of Health, Lab...

ProStent Coronary Drug-Eluting Stent
https://clinicaltrials.gov/ct2/show/NCT00887211

Apr 30th, 2009 - A single blind, multi-center, randomized study is preformed to compare ProStent drug-eluting stents with Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd. to evaluate the safety and efficacy of ProStent drug-eluting stent in...

see more →

News  3 results

BIOFLOW V: Orsiro outperforms Xience stent
https://www.mdedge.com/cardiology/article/178950/interventional-cardiology-surgery/bioflow-v-orsiro-outperforms-xience
Susan London

Nov 5th, 2018 - SAN DIEGO – Seemingly nuanced differences between drug-eluting stents can translate to substantial differences in clinical outcomes longer term, updated results of the BIOFLOW V randomized trial reported at the Transcatheter Cardiovascular Therape.

Reigning Coronary DES King Matches Its Predecessor
https://www.mdedge.com/internalmedicine/article/37228/cardiology/reigning-coronary-des-king-matches-its-predecessor
Mitchel L. Zoler, PhD

Aug 30th, 2011 - PARIS – The current master of the coronary drug-eluting stent universe, the everolimus-eluting stent, finally proved itself fully worthy of its position, matching the efficacy and safety performance of its predecessor, the sirolimus-eluting corona.

Coronary Drug-Eluting Stent Safety Diminishes Over Time
https://www.medpagetoday.com/cardiology/pci/12228

Dec 18th, 2008 - Action Points Explain to interested patients that this study suggests that both drug-eluting and bare-metal stents have good long-term safety profiles. Explain to patients who ask that a number of factors influence the choice of stent type. Explai...

see more →